Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Ultragenyx Pharmaceu (RARE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Ultragenyx Pharmaceu 60 Leveroni Court Novato CA 94949 USA

P: 415-483-8800 F: 415-483-8810

Description:

Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company's product pipeline include KRN23 (UX023) for the treatment of XLH, rhGUS (UX003) for the treatment of MPS 7, rhPPCA (UX004) for the treatment of galactosialidosis, Triheptanoin (UX007) for the treatment of LC-FAOD, Triheptanoin (UX007) for the treatment of Glut1 DS and SA-ER (UX001) for the treatment of HIBM which are in different clinical phases. Ultragenyx Pharmaceutical Inc. is headquartered in Novato, California.

Key Statistics

Overview:

Market Capitalization, $K 3,303,906
Shares Outstanding, K 51,279
Annual Sales, $ 51,500 K
Annual Net Income, $ -197,610 K
Last Quarter Sales, $ 16,260 K
Last Quarter Net Income, $ -87,830 K
60-Month Beta 2.22
% of Insider Shareholders 8.40%
% of Institutional Shareholders 98.62%
Float, K 46,972
% Float 91.60%

Growth:

1-Year Return 17.34%
3-Year Return -15.25%
5-Year Return 82.78%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 50.30%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.73 on 02/19/19
Next Earnings Date 05/06/19
Earnings Per Share ttm -4.72
EPS Growth vs. Prev Qtr 0.57%
EPS Growth vs. Prev Year 23.79%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00

RARE Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward -17.52
Price/Earnings to Growth N/A
Return-on-Equity (After Tax) -35.26
Return-on-Assets (Before Tax) -30.62
Profit Margin % -383.71
Net Margin % N/A
Debt/Equity 0.00
Price/Sales 64.44
Price/Cash Flow N/A
Price/Book 5.38
Book Value/Share 12.04
Interest Coverage N/A
Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar